Other approaches including anti-aggregation agents (β-sheet breakers e.g., HPYD or aggregation inhibitor like ALZ-801), anti-inflammatory agents (e.g., MLC901), Tau protein aggregation inhibitors (e.g., TRx0237), neuroprotective agents and autophagy inducers are currently in different phases of the Alzheimer’s disease drug development pipeline, for example reviewed in detail in Cummings et al. 2019 [40], on https://clinicaltrials.gov, https://www.alzforum.org or https://www.alz.org/. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.